| Item 7.01 | Regulation FD Disclosure. |
On December 17, 2024, Biomea Fusion, Inc. (the “Company”) issued a press release announcing topline data from the Phase II portion of COVALENT-111, the Company’s clinical trial of its lead product candidate, icovamenib, in type 2 diabetes. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The Company also hosted a conference call and live webcast to discuss the interim clinical data on December 17, 2024 at 8:00 a.m. E.T. The Company has made available a slide presentation to accompany the call, a copy of which is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
On December 17, 2024, the Company reported positive topline results from its ongoing Phase II COVALENT-111 Study in patients with type 2 diabetes (“T2D”). Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c at Week 26 in the prespecified per protocol patient population. Specifically, Arm B, the larger patient set from the two 12-week dosing arms, demonstrated a statistically significant reduction in HbA1c compared to placebo in all patients treated in the Per Protocol Patient population. In a post-hoc analysis of patients receiving at least one anti-diabetic medication, all active dosing arms combined as well as Arm B demonstrated a statistically significant reduction in HbA1c compared to placebo. Best response was achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline (Arm B, n=7), showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing with 100 mg icovamenib. Additionally it was noted that icovamenib was generally well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events, and no related serious adverse events.
The purpose of COVALENT-111 is to identify the optimal dose and the patient population to advance with icovamenib in late-stage clinical development. The topline data at Week 26 supports that 12-weeks of treatment of consistent 100 mg once-daily exposure, Arm B, was the best performing dose scheme, and the insulin-deficient patient population (SIDD and MARD patients) were the best responding subjects. The SIDD and MARD subgroups are known to demonstrate the lowest beta-cell function and lowest fasting c-peptide of the four phenotypes. COVALENT-111 is a double-blinded, randomized, 3:1 placebo-controlled trial that has enrolled adult patients diagnosed with T2D within the last 7 years, who had HbA1c levels between 7.0% and 10.5%, and a body mass index (BMI) between 25 and 40 kg/m². At baseline, all participants were receiving treatment with diet and exercise and were uncontrolled with up to three antidiabetic medications. Icovamenib was investigated in three different dosing arms with a primary follow up after 26 weeks, which the Company reported on: Arm A at 100mg QD (once daily) for 8 weeks, Arm B at 100mg QD for 12 weeks, and Arm C at 100 mg QD for 8 weeks and 100mg BID (twice daily) for 4 weeks. The study enrolled a total of 225 patients who received at least one dose of icovamenib and were considered evaluable for the modified intent-to-treat population. Dosing was interrupted for many patients due to an interim clinical hold imposed by the U.S. Food and Drug Administration (the “FDA”). This topline efficacy analysis focuses on those patients who had completed at least 80% of their assigned dosing schedule prior to the clinical hold, the Per Protocol Patient population, and includes a post-hoc analysis of the subgroup (90% of Per Protocol Patients) who were treated with one or more anti-hyperglycemic therapies at baseline (n=168).
Based on these initial results and the upcoming 52-week readout in the second half 2025, we plan to engage with the FDA to discuss the data. This meeting will provide an opportunity to align with FDA on how to further advance icovamenib as a first-in-class menin inhibitor therapy for T2D.
